Treats T. vaginalis infection in females and males. ANDA 76522, held by Chartwell RX. Metronidazole.
As of Nov 21, 2026, ANDA 76522 (Metronidazole), held by Chartwell RX, was first approved by FDA on Jan 29, 2004, with 4 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Symptomatic Trichomoniasis. METRONIDAZOLE capsules are indicated for the treatment of T. vaginalis infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis. METRONIDAZOLE capsules are indicated in the treatment of asymptomatic T. vaginalis infection in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 29, 2004 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Metronidazole375MG · capsule;oral | Metronidazole | Rx |
| Nov 27, 2023 | Supplement 11Labeling · Standard review | Approved | None posted |
| Oct 22, 2010 | Supplement 8Labeling | Approved | None posted |
| Jun 27, 2007 | Supplement 6Labeling | Approved | None posted |
| Jan 21, 2005 | Supplement 2Labeling | Approved | None posted |
| Jan 29, 2004 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters